Medco Health Solutions — Thomas Weisel Partners Healthcare Conference 2007
21 slides from Medco Health Solutions's conference presentation, Sep 5, 2007

Slide 1: Thomas Weisel Partners Healthcare Conference 2007
Thomas Weisel Partners Healthcare Conference 2007 Boston September 5, 2007 Medco is a registered trademark of Medco Health Solutions, Inc. Timothy C. Wentworth President & Chief Executive Officer Accredo Health Group, Inc. Richard J. Rubino Senior Vice President and Controller, Chief Accounting Offi

Slide 2: Forward-looking statements
Forward-looking statements This presentation contains “forward-looking statements” as that term is defined in the Private Securities Litigation Reform Act of 1995. These statements involve risks and uncertainties that may cause results to differ materially from those set forth in the statements. No

Slide 3: Forward-looking statements (continued)
Forward-looking statements (continued) This presentation also contains forward-looking statements regarding the benefits of the proposed transaction with PolyMedica Corporation, expected synergies, anticipated future financial and operating performance and results. These statements are based on the

Slide 4: Forward-looking statements (continued)
Forward-looking statements (continued) Other unknown or unpredictable factors also could have material adverse effects on future results, performance or achievements of the two companies. As required by SEC rules, we have posted this document, including certain supplemental information, on the Inves

Slide 5: Additional Information and Where to Find It
Forward-looking statements (continued) Additional Information and Where to Find It This presentation may be deemed to be solicitation material in respect of the proposed acquisition of PolyMedica by Medco. In connection with the proposed acquisition, Medco and PolyMedica intend to file relevant mate

Slide 6: Forward-looking statements (continued)
Forward-looking statements (continued) Medco and its directors and executive officers, and PolyMedica and its directors and executive officers, may be deemed to be participants in the solicitation of proxies from the holders of PolyMedica common stock in respect of the proposed transaction. Informat

Slide 7: Pharmacy industry trends
Pharmacy industry trends Aging of America By 2010, seniors aged 55-64 will increase by nearly 50% ¹ Seniors consume 3 times the average drug spend of younger consumers (more than 30 Rx’s each) Drug spend inflation & the need to control costs CMS projects drug spend to increase by 8% annually through

Slide 8: The Medco advantage
The Medco advantage Scale at mail service; two patented, fully integrated state-of-the-art automated dispensing facilities Superior clinical strategy driving superior trend performance Innovative client solutions . . . My RxChoices, EXPERxT Advisor®, Optimal Health Industry-leading transparency Inte

Slide 9: EBITDA per adjusted script
$1.83 $1.89 $2.24 $2.77 $1.50 $1.30 $1.50 $1.70 $1.90 $2.10 $2.30 $2.50 $2.70 $2.90 $3.10 2003 2004 2005 2006* June YTD 2007 EBITDA per adjusted script * Excludes first-quarter 2006 legal settlements charge; see reconciliation to GAAP financial tables in appendix on page 22

Slide 10: Medco growth drivers
Leading Medicare solutions Medco growth drivers High-touch specialty pharmacy High-tech mail-order pharmacies Generics leadership Innovation for a greater tomorrow Client focus: new business and renewals

Slide 11: Generic growth opportunity
Generic growth opportunity Over $63B brand drugs off-patent 2007-2012 Off-patent compounding effect ($ Billions, prorated) 16.1 9.3 5.1 13.0 4.1 18.9 13.1 2006 2007 2008 2009 2010 2011 2012 $63B in US off-patent Brand-name drug spend ($ Billions, annualized) Zocor ® Zoloft ® Risperdal ® 6.8 13.4 13.

Slide 12: Robust biotechnology drug pipeline
Robust biotechnology drug pipeline Over 400 drugs in development <1 11 33 82 1995 2000 2006E 2010E Specialty pharmacy drug spend* ($ in billions) CAGR 1995-2010 = 34.1% More than 400 drugs in development pipeline* Source: Medco Estimates. *Excludes oncology spend of approximately $20 - $25B. *Source

Slide 13: Medicare programs
Medicare programs 2Q07 total lives under management Medicare Part D PDP Health plan and employer PDP partners Medicare-eligible in commercial base 2Q07 revenues $13.7B 2006 Revenues 7.7MM: 330k 840k 6.5MM $3.4B

Slide 14: New business and renewals
New business and renewals * $1.7B New annualized business for 2007 Average Mail pen rate of 37.8 percent Renewed nearly 95% of drug spend scheduled to renew in 2007 96.3% Client retention rate – Average contract length 4.5 years * As of second-quarter 2007.

Slide 15: Engage those who generate the cost
Engage those who generate the cost 0% 10% 20% 30% 40% 50% 60% 70% 80% 90% 100% % Members % Rx Cost 3% 1% 3% Complex Chronic Acute Well 46% 17% 34% 16% 80%

Slide 16: Historical approach
Pharmacists Physicians General Pharmacy Site General Pharmacy Site General Pharmacy Site General Pharmacy Site General Pharmacy Site General Pharmacy Site General Pharmacy Site Historical approach Pharmacists Patients Physicians

Slide 17: The new frontier in pharmacy practice
Accredo Columbus • Hypertension N. Versailles Specially Trained Pharmacists Physicians The new frontier in pharmacy practice Healthcare Value Map Fairfield • High Risk Texas • High Risk Tampa • High Cholesterol Spokane Rare & Specialty 0.19 MM Patients 42 Sites Hematology Oncology 0.6 MM Patients Co

Slide 18: PolyMedica acquisition
PolyMedica acquisition On August 28, 2007, Medco announced the strategic acquisition of Polymedica for $53 per share or $1.5 billion in all-cash transaction To combine Medco’s advanced pharmacy practice with leading source for diabetes-care services and supplies To leverage Medco’s Therapeutic Resou

Slide 19: PolyMedica acquisition
PolyMedica acquisition Medco serves approximately 2.8 million diabetics; Polymedica serves approximately 1 million Combined, Medco and Polymedica will serve more than 20 percent of the 17 million patients diagnosed with diabetes Diabetes pharmacy and related market is estimated to be in excess of $2

Slide 20: Medco
medco

Slide 21: Reconciliation Tables
Reconciliation Tables 688.2 - $ 1,035.7 94.3 189.0 302.9 23.7 ³ $ 425.8 December 27, 2003 Full Year Ended 678.3 714.1 729.9 375.7 Adjusted prescriptions 8 - - 162.6 - Legal settlements charge 7 $ 1,243.7 $1,350.3 $ 1,469.8 $ 1,041.3 EBITDA 179.9 192.5 218.5 109.3 Amortization expense 197.6 165.0 173
Source: SEC EDGAR · 8-K filed Sep 5, 2007
More decks from Medco Health Solutions Inc
Merger or Acquisition (July 2011)20 slides · Jul 22, 2011
Sanford C. Bernstein 27th Annual Strategic Decisions Conference 201125 slides · Jun 1, 2011
Deutsche Bank 36th Annual Health Care Conference 201130 slides · May 3, 2011
Investor Presentation (March 2011)36 slides · Mar 24, 2011
Barclays Capital 2011 Global Health Care Conference36 slides · Mar 17, 2011
Citi 2011 Global Health Care Conference37 slides · Mar 1, 2011